<DOC>
	<DOCNO>NCT00932022</DOCNO>
	<brief_summary>This study evaluate effectiveness trospium chloride extend release ( XR ) obese female patient overactive bladder ( OAB ) . Patients receive either placebo trospium chloride XR placebo . The study assess change baseline urinary frequency , urgency , incontinence trospium chloride XR versus placebo-pill . The study 14 week duration .</brief_summary>
	<brief_title>Trospium Chloride XR Obese Female Patients With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Trospium chloride</mesh_term>
	<criteria>OAB syndrome Urgency , Urinary frequency Urgency urinary incontinence Nonsmoker ( refrain tobacco usage , include smokeless tobacco , nicotine patch , etc. , 6 month prior screen visit ) . Obese Chronic kidney failure Abdominal bypass surgery obesity Moderate severe memory impairment Uncontrolled narrow angle glaucoma Uncontrolled systemic disease Concurrent dementia drug : Aricept ( donepezil ) , Namenda ( memantine ) , Cognex ( tacrine ) , Exelon ( rivastigmine ) , Razadyne ( galantamine ) , similar drug dementia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>